Shire
Shire says new plant will add to Replagal, Vpriv capacity
January 17, 2011Manufacturing and Production Cerezyme, Replagal, Shire, Vpriv
UK drugmaker Shire has completed construction of a new manufacturing facility for its orphan disease drugs Replagal and Vpriv, and …
Pfizer submits Gaucher drug to EMA
November 29, 2010Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa
Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …
Philip Vickers joins Shire
October 13, 2010Research and Development Shire, appointment, research and development
Shire has appointed Philip Vickers as senior VP of research and development for its Human Genetic Therapies (HGT) business. He …
FDA already notified on ProAmatine withdrawal, says Shire
August 18, 2010Sales and Marketing FDA, ProAmatine, Shire
Shire is to withdraw its product ProAmatine following a demand from the FDA early this week regarding post-marketing data on …
FDA considers pulling ProAmantine
August 17, 2010Sales and Marketing FDA, Shire, post-marketing
Shire’s low blood pressure drug ProAmantine and generic copies could be withdrawn from the US market because no post-marketing studies …
Shire profits from Genzyme woes
August 5, 2010Sales and Marketing Shire
Specialist pharma company Shire has posted a set of strong results, thanks in part to the gains it has made …
Shire moves in on Movetis
August 5, 2010Research and Development, Sales and Marketing Movetis, Shire
Shire has made a €428 million offer for Belgium-based Movetis in a bid to grow its business in Europe and …
Shire’s Vpriv recommended for European approval
June 28, 2010Sales and Marketing Brinavess, Gaucher, Rapiscan, Ruconest, Shire, Sycrest
Shire has won backing from a key European regulatory committee for its new Gaucher disease orphan drug. Vpriv was one …
Working Life: Jo Ferdinando
June 22, 2010Manufacturing and Production, Research and Development Shire, Working Life, careers
How did you find your way into your most current role? After completing a BSc in Microbiology and Virology at …
Shire revenue dips after generic Adderall hit
April 30, 2010Sales and Marketing Adderall, Fabrazyme, Gaucher's, Shire
Shire’s first quarter revenues fell by 5% after its ADHD treatment Adderall XR succumbed to generic competition from Teva. This …
Bill Burns joins Shire board
March 17, 2010Research and Development, Sales and Marketing Shire, appointment, research and development, sales and marketing
Former Roche pharma chief executive Bill Burns has joined the board at Shire as a non-executive director. Burns has also …
Shire launches Vpriv to capitalise on Genzyme woes
March 2, 2010Sales and Marketing Cerezyme, Gaucher's, Shire
Shire has gained US approval to launch Vpriv, its new treatment for Gaucher’s disease, which it hopes will steal market …
Shire readies Gaucher drug Vpriv
February 23, 2010Manufacturing and Production Cerezyme, Gaucher's, Shire, Vpriv
Shire Pharmaceuticals says it has already manufactured enough of its Vpriv to treat around 400 Gaucher disease patients and could …
Low Adderall sales hit Shire
February 22, 2010Sales and Marketing 2009 financials, Adderall, Shire
Shire has posted negative growth due to generic competition for its flagship ADHD drug Adderall XR. Product sales were down …
Digital Pharma: Byte-sized roundup
January 8, 2010Medical Communications Diabetes UK, NICE, Shire, ViiV, digital pharma, doctors.net, iphone
Includes online petition against NICE decision, Shire brings ADHD to Twitter, ViiV joins Twitter, Doctors.net.uk launches iPhone app and Diabetes …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
